Details
The value behind a comprehensive assessment of the genomic alterations in a tumor has been consistently increasing with the availability of new therapeutic agents and better predictability of response. The regulatory and reimbursement for this type of assay evolved drastically over the last years. We will discuss how this change in environment provides strong value to adopt comprehensive genomic profiling in today's oncology care.
Presented by:
Phil Febbo, MD
Chief Medical Officer
Illumina, Inc.
Maude Champagne
Clinical Oncology Marketing
Illumina, Inc.
Fill Out Form to Access Webinar
Your email address is never shared with third parties.
- Date & Time
- Nov 14, 2018
- 10:00 AM
- Location
- North America
- Topic
- Oncology